Real-World Utilization Patterns of Oncology Biosimilar Monoclonal Antibodies and Their Corresponding Reference Products
Yang J1, Thompson J2, Maculaitis MC3, Alvir JM4, Shelbaya A1, Kelton JM1
1Pfizer Inc, New York, NY, USA, 2Cerner Enviza, Providence, RI, USA, 3Cerner Enviza, Malvern, PA, USA, 4Pfizer Inc, Statistical Research and Data Science Center, New York, NY, USA
OBJECTIVES: Multiple oncology biosimilar monoclonal antibodies (mAbs) are now available for use as therapeutic options with comparable safety/efficacy profiles to that of their reference biologics. The objective of this study was to describe real-world treatment pattens of rituximab-pvvr, trastuzumab-qyyp, and bevacizumab-bvzr and their associated reference biologics.
METHODS: Closed claims data from Komodo Health from 11/1/2018-5/1/2021 were used for this study. Patients age ≥18, who were newly initiating therapy with a biosimilar (rituximab-pvvr/trastuzumab-qyyp/bevacizumab-bvzr) or the reference biologics (rituximab/trastuzumab/bevacizumab) between 11/1/2019-11/1/2020 for an indicated oncology diagnosis, who had continuous insurance eligibility 360-days pre-mAb-index through 180-days post-mAb-index, were included. Treatment patterns assessed included time-to-therapy-initiation from index diagnosis (identified during 360-day pre-mAb-index period), concomitant medication-use including drug regimens, and switching patterns.
RESULTS: A total of 585 and 5621 patients initiating therapy with a biosimilar or reference-biologic were included, respectively. The biosimilar-initiator/reference-biologic-initiator cohorts both displayed utilization across all similarly-indicated oncology diagnoses, with the largest diagnosis-cohorts for rituximab-indicated, trastuzumab-indicated, and bevacizumab-indicated conditions being non-Hodgkin’s lymphoma (NHL) [rituximab-pvvr=304(91.0%); rituximab=2151(90.8%)], breast cancer (BC) [trastuzumab-qyyp=105(91.3%); trastuzumab=878(94.5%)], and colorectal cancer (CRC) [bevacizumab-bvzr=86(63.2%); bevacizumab=1333(57.4%)]. Time-to-therapy-initiation was similar for both biosimilar-initiators and reference-biologic-initiators for patients with NHL [(rituximab-pvvr mean days=119; SD=123), (rituximab mean days=123; SD=127)], BC [(trastuzumab-qyyp mean days=91; SD=96), (trastuzumab mean days=97; SD=98)], and CRC [(bevacizumab-bvzr mean days=171; SD=144), (bevacizumab mean days=202; SD=141)]. Both originator and biosimilar products were used along with specific drug regimens for NHL (CHOP, CVP, DHAP), BC (docetaxel+carboplatin+pertuzumab, docetaxel+carboplatin, pertuzumab+paclitaxel/docetaxel), and CRC (FOLFOX, CAPOX, FOLFIRI, FOLFOXIRI). Switching among biologics was also observed; the proportion of patients who utilized a different manufacturer-produced mAb-biologic following initiation with the biosimilar or reference-biologic were: 6.9% and 7.4% for NHL, 17.4% and 21.9% for BC, and 2.3% and 12.2% for CRC, respectively.
CONCLUSIONS: Biosimilar-mAb products are being utilized in a manner similar to their reference biologic-mAbs in real-world clinical settings.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Biologics and Biosimilars